comparemela.com

Latest Breaking News On - Strategy outlook - Page 2 : comparemela.com

Fiduciary Management International Equity Q1 2022 Investment Letter

Fiduciary Management International portfolios fell by ~5.3% (gross)/5.4% (net) hedged & 7.4% (gross)/7.6% (net) unhedged. Click here to read the full fund letter.

United statesFrance generalUnited kingdomDain tofsonAkzo nobelVladimir putinBen grahamHoldings incIndustrial servicesInternational equityEuropean central bankSamsung electronics coDistribution servicesTaiwan semiconductor mfgChubb ltdSchlumberger ltd

Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021

OCTOBER-DECEMBER IN SUMMARY Net sales for the period amounted to KSEK - (-).Result for the period amounted to KSEK -32,844 (-47,880).Earnings and diluted earnings per share totaled SEK -0.16 (-0.58).Immunicum

Mario brkuljErik mantingBrendan payneSociety for immunotherapy of cancerValency communicationsYear end resultsLotta fermChief financialGastrointestinal stromal tumorsStrategy outlookEnd reportReport januaryGeneral meetingSwedish securities market act

Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021

OCTOBER-DECEMBER IN SUMMARY Net sales for the period amounted to KSEK - (-).Result for the period amounted to KSEK -32,844 (-47,880).Earnings and diluted earnings per share totaled SEK -0.16 (-0.58).Immunicum

Mario brkuljErik mantingBrendan payneSociety for immunotherapy of cancerValency communicationsLotta fermChief financialGastrointestinal stromal tumorsStrategy outlookEnd reportReport januaryGeneral meetingSwedish securities market act

Investegate |Immunicum AB Announcements | Immunicum AB: Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021

Investegate announcements from Immunicum AB, Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021

Mario brkuljErik mantingBrendan payneSociety for immunotherapy of cancerValency communicationsYear end resultsLotta fermChief financialGastrointestinal stromal tumorsStrategy outlookEnd reportReport januaryGeneral meetingSwedish securities market actInvestegate announcementsInvestegate company announcements

Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021

OCTOBER-DECEMBER IN SUMMARY Net sales for the period amounted to KSEK - (-).Result for the period amounted to KSEK -32,844 (-47,880).Earnings and diluted earnings per share totaled SEK -0.16 (-0.58).Immunicum

Mario brkuljErik mantingBrendan payneSociety for immunotherapy of cancerValency communicationsLotta fermChief financialGastrointestinal stromal tumorsStrategy outlookEnd reportReport januaryGeneral meetingSwedish securities market act

vimarsana © 2020. All Rights Reserved.